UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 144

Sortiert nach

Bone health in estrogen-free contraception

Osteoporosis international, 2019-12, Vol.30 (12), p.2391-2400

2019

Volltextzugriff (PDF)

Bleeding profile of women using a drospirenone-only pill 4 mg over nine cycles in comparison with desogestrel 0.075 mg

PloS one, 2020-06, Vol.15 (6), p.e0231856

2020

Volltextzugriff (PDF)

Comparative pharmacokinetic estimates of drospirenone alone and in combination with ethinyl estradiol after single and repeated oral administration in healthy females

Contraception (Stoneham), 2020-02, Vol.101 (2), p.137-143

2020

Volltextzugriff (PDF)

Correction to: Bone health in estrogen-free contraception

Osteoporosis international, 2020-07, Vol.31 (7), p.1399-1399

2020

Volltextzugriff (PDF)

Evaluation of the food effect on a drospirenone only contraceptive containing 4 mg administered with and without high-fat breakfast in a randomised trial

BMC women's health, 2022-09, Vol.22 (1), p.1-381, Article 381

2022

Volltextzugriff (PDF)

10-month retrospective study on compliance and tolerability of the drospirenone-only pill

European review for medical and pharmacological sciences, 2023-04, Vol.27 (7), p.2987

2023

Volltextzugriff (PDF)

Multicenter, international observational study on quality of life and acceptability of a vaginal contraceptive ring containing etonogestrel/ethinylestradiol 11.00/3.474 mg over six months of use

European review for medical and pharmacological sciences, 2022-10, Vol.26 (19), p.7204

2022

Volltextzugriff (PDF)

Progesterone in Peri- and Postmenopause: A Review

Geburtshilfe und Frauenheilkunde, 2014-11, Vol.74 (11), p.995-1002

Regidor, P.-A.

2014

Volltextzugriff (PDF)

Elution from intact and broken vaginal contraceptive rings: an in vitro study

European review for medical and pharmacological sciences, 2020-05, Vol.24 (10), p.5668

2020

Volltextzugriff (PDF)

Drospirenone 4 mg in a 24/4 regimen maintains inhibition of ovulation even after a 24-h delay pill intake - Pharmacological aspects and comparison to other progestin-only pills

European review for medical and pharmacological sciences, 2022-03, Vol.26 (6), p.1994

2022

Volltextzugriff (PDF)

Reply Letter - to Urso et al "Comment on: Comparative dissolution profiles of two anti-emetic delayed release dosage forms of doxylamine and pyridoxine: Xonvea® tablets vs. Cariban® capsules"

European review for medical and pharmacological sciences, 2022-12, Vol.26 (23), p.8635

2022

Volltextzugriff (PDF)

Reduced proliferation and cell adhesion in endometriosis

Molecular human reproduction, 2000-07, Vol.6 (7), p.610-617

2000

Volltextzugriff (PDF)

Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis

Gynecological endocrinology, 2001-06, Vol.15 (3), p.202-209

2001

Volltextzugriff (PDF)

Expression pattern of integrin adhesion molecules in endometriosis and human endometrium

Human reproduction update, 1998-09, Vol.4 (5), p.710-718

1998

Volltextzugriff (PDF)

Progesterone in Peri- and Postmenopause: A Review

Geburtshilfe und Frauenheilkunde, 2014-11, Vol.74 (11), p.995-1002

Regidor, P.-A.

2014

Volltextzugriff (PDF)

The clinical relevance of progestogens in hormonal contraception: Present status and future developments

Oncotarget, 2018-10, Vol.9 (77), p.34628-34638

Regidor, Pedro-Antonio

2018

Volltextzugriff (PDF)

Aberrant expression pattern of gap junction connexins in endometriotic tissues

Molecular human reproduction, 1997-05, Vol.3 (5), p.375-381

1997

Volltextzugriff (PDF)

Peritoneal endometriosis: validation of an in-vivo model

Human reproduction (Oxford), 2001-08, Vol.16 (8), p.1736-1743

2001

Volltextzugriff (PDF)

Verschreibungsverhalten deutscher Frauenärzte und Veränderungen in der Behandlung menopausaler Beschwerden. Eine offene, retrospektive Umfrage

Geburtshilfe und Frauenheilkunde, 2018, Vol.78 (10)

Regidor, PA

2018

Volltextzugriff (PDF)

Long-term follow-up on the treatment of endometriosis with the GnRH-agonist buserelinacetate Long-term follow-up data (up to 98 months) of 42 patients with endometriosis who were treated with GnRH-agonist buserelinacetate (Suprecur®), were evaluated in respect of recurrence of pain symptoms and pregnancy outcome

European journal of obstetrics & gynecology and reproductive biology, 1997-06, Vol.73 (2), p.153-160

1997

Volltextzugriff (PDF)

Drospirenon als Östrogen freie Pille und Hämostase. Untersuchung zur Koagulation zwischen einer neuen 4 mg Formulierung in einem 24+4 Zyklus versus 75 µg Desogestrel

Geburtshilfe und Frauenheilkunde, 2016, Vol.76 (10)

Regidor, PA

2016

Volltextzugriff (PDF)

Morphometric analyses of endometriotic tissues to determine their grade of activity

Gynecological endocrinology, 2002-06, Vol.16 (3), p.235-243, Article 235

2002

Volltextzugriff (PDF)

Elution from intact and broken vaginal contraceptive rings: an in vitro study

Geburtshilfe und Frauenheilkunde, 2020, Vol.80 (10)

2020

Volltextzugriff (PDF)

E- and P-selectin expression in endometriotic tissues and the corresponding endometria

Gynecological endocrinology, 2000, Vol.14 (2), p.111-117

2000

Volltextzugriff (PDF)

Hemmung der Ovulation mit einer neuen Östrogen freien Pille mit 4 mg Drospirenon trotz geplanter 4 tägiger nicht Einnahme in einem 28 Tages Zyklus

Geburtshilfe und Frauenheilkunde, 2016

Regidor, PA

2016

Volltextzugriff (PDF)

1 – 25 von 144

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(110)
Mit Volltextzugriff
(77)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Bone health in estrogen-free contraception

Bleeding profile of women using a drospirenone-only pill 4 mg over nine cycles in comparison with desogestrel 0.075 mg

Comparative pharmacokinetic estimates of drospirenone alone and in combination with ethinyl estradiol after single and repeated oral administration in healthy females

Correction to: Bone health in estrogen-free contraception

Evaluation of the food effect on a drospirenone only contraceptive containing 4 mg administered with and without high-fat breakfast in a randomised trial

10-month retrospective study on compliance and tolerability of the drospirenone-only pill

Multicenter, international observational study on quality of life and acceptability of a vaginal contraceptive ring containing etonogestrel/ethinylestradiol 11.00/3.474 mg over six months of use

Progesterone in Peri- and Postmenopause: A Review

Elution from intact and broken vaginal contraceptive rings: an in vitro study

Drospirenone 4 mg in a 24/4 regimen maintains inhibition of ovulation even after a 24-h delay pill intake - Pharmacological aspects and comparison to other progestin-only pills

Reply Letter - to Urso et al "Comment on: Comparative dissolution profiles of two anti-emetic delayed release dosage forms of doxylamine and pyridoxine: Xonvea® tablets vs. Cariban® capsules"

Reduced proliferation and cell adhesion in endometriosis

Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis

Expression pattern of integrin adhesion molecules in endometriosis and human endometrium

Progesterone in Peri- and Postmenopause: A Review

The clinical relevance of progestogens in hormonal contraception: Present status and future developments

Aberrant expression pattern of gap junction connexins in endometriotic tissues

Peritoneal endometriosis: validation of an in-vivo model

Verschreibungsverhalten deutscher Frauenärzte und Veränderungen in der Behandlung menopausaler Beschwerden. Eine offene, retrospektive Umfrage

Drospirenon als Östrogen freie Pille und Hämostase. Untersuchung zur Koagulation zwischen einer neuen 4 mg Formulierung in einem 24+4 Zyklus versus 75 µg Desogestrel

Morphometric analyses of endometriotic tissues to determine their grade of activity

Elution from intact and broken vaginal contraceptive rings: an in vitro study

E- and P-selectin expression in endometriotic tissues and the corresponding endometria

Hemmung der Ovulation mit einer neuen Östrogen freien Pille mit 4 mg Drospirenon trotz geplanter 4 tägiger nicht Einnahme in einem 28 Tages Zyklus

Suchergebnisse filtern